Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664182 · ClinicalTrials.gov registry record · Phase 2
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01664182: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01664182 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01664182, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate works in treating patients with kidney cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. Immunotherapy with monoclonal, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pazopanib hydrochloride, sorafenib tosylate, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. It is not yet known whether giving trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate is more effective in treating kidney cancer.
Interventions
- BIOLOGICAL Bevacizumab
- DRUG Pazopanib Hydrochloride
- DRUG Sorafenib Tosylate
- DRUG Sunitinib Malate
- BIOLOGICAL Trebananib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2020-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664182
The ClinicalTrials.gov registry entry for NCT01664182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01664182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664182 about?
NCT01664182 is a clinical study titled "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer". This randomized phase II trial studies how well trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate works in treating patients with kidney cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment ...
What is the current status of trial NCT01664182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2012-08-01. Estimated completion is 2020-12-07.
What interventions are being tested in trial NCT01664182?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Pazopanib Hydrochloride (DRUG), Sorafenib Tosylate (DRUG), Sunitinib Malate (DRUG), Trebananib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01664182?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.